SCHEMBL21296769

SCHEMBL21296769

O=C(Nc1ccccc1-c1[nH]ncc1Cl)c1ccc(OCCN2CCCCC2)cc1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 3/20 0.51
BRD4 O60885 1/20 0.49
JAK1 P23458 1/20 0.49
HDAC1 Q13547 1/20 0.49
PSMB1 P20618 2/20 0.47
PSMB5 P28074 2/20 0.47
LTA4H P09960 1/20 0.47
PSMB2 P49721 1/20 0.47
KCNA5 P22460 2/20 0.47
AURKA O14965 3/20 0.46
KDR P35968 3/20 0.46
FLT3 P36888 2/20 0.46
HRH3 Q9Y5N1 2/20 0.46
ADRA1D P25100 2/20 0.45
ADRA1A P35348 2/20 0.45
ADRA1B P35368 2/20 0.45
KDM4E B2RXH2 1/20 0.45
FLT1 P17948 1/20 0.44
TGFBR1 P36897 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21296831 0.89 MCHR1 (0.51) MCHR1BRD4JAK1HDAC1PSMB1
SCHEMBL21296780 0.88 ADRA1D (0.54) MCHR1BRD4JAK1HDAC1PSMB1
SCHEMBL21296795 0.88 MCHR1 (0.50) MCHR1BRD4JAK1HDAC1PSMB1
SCHEMBL21296760 0.88 MCHR1 (0.50) MCHR1BRD4JAK1HDAC1PSMB1
SCHEMBL21296811 0.87 MCHR1 (0.49) MCHR1BRD4JAK1HDAC1PSMB1
SCHEMBL21296835 0.86 ESR1 (0.50) MCHR1BRD4JAK1HDAC1PSMB1
SCHEMBL21296804 0.86 MCHR1 (0.51) MCHR1BRD4JAK1HDAC1PSMB1
SCHEMBL21296819 0.83 MCHR1 (0.54) MCHR1BRD4JAK1HDAC1PSMB1
SCHEMBL21296789 0.82 MCHR1 (0.51) MCHR1BRD4JAK1HDAC1PSMB1
SCHEMBL21296824 0.82 KDR (0.58) MCHR1BRD4JAK1HDAC1PSMB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240246943-A1 MULTIFACETED APPROACH TO NOVEL INTERLEUKIN-6 INHIBITORS University of Florida Research Fooundation, Incorporated (US) 2024-07-25 US disclosed
US-11530181-B2 IL-6 inhibitors and methods of treatment UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2022-12-20 US disclosed
US-11530181-B2 IL-6 inhibitors and methods of treatment UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2022-12-20 US disclosed
WO-2022226133-A1 MULTIFACETED APPROACH TO NOVEL INTERLEUKIN-6 INHIBITORS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2022-10-27 WO disclosed
US-20210206718-A1 IL-6 INHIBITORS AND METHODS OF TREATMENT UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED 2021-07-08 US disclosed
US-20210206718-A1 IL-6 INHIBITORS AND METHODS OF TREATMENT UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED 2021-07-08 US disclosed
WO-2019165158-A1 IL-6 INHIBITORS AND METHODS OF TREATMENT UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2019-08-29 WO disclosed
WO-2019165158-A1 IL-6 INHIBITORS AND METHODS OF TREATMENT UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2019-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11530181-B2 IL-6 inhibitors and methods of treatment IL6, IL6ST, IL2 MCHR1 1328/4885BRD4 562/4885JAK1 68/4885
US-20240246943-A1 MULTIFACETED APPROACH TO NOVEL INTERLEUKIN-6 INHIBITORS IL6, IL6ST, IL36G MCHR1 2394/4885BRD4 953/4885JAK1 43/4885
US-20210206718-A1 IL-6 INHIBITORS AND METHODS OF TREATMENT IL6, IL6ST, IL2 MCHR1 1328/4885BRD4 562/4885JAK1 68/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.